Patents Examined by Johnnie R. Brown
  • Patent number: 5208327
    Abstract: This invention relates to a novel process for preparing 2-chloro-2'-deoxyadenosine (2-CdA) having the following formula ##STR1## from a compound of the following formula ##STR2## The invention also relates to intermediates which are useful in preparing 2-CdA. The compound 2-CdA is useful as an antileukemic agent, i.e., in treating leukemias, such as hairy cell leukemia.
    Type: Grant
    Filed: April 16, 1992
    Date of Patent: May 4, 1993
    Assignee: Ortho Pharmaceutical Corporation
    Inventor: Robert H. K. Chen
  • Patent number: 5208021
    Abstract: A potent and specific immunotoxin is prepared by coupling an inactivated diphteria toxin to a binding moiety such as a monoclonal antibody or transferrin. The immunotoxins are specific for human tumors and leukemias and are indistinguishable in cell toxicity from that of the native toxin linked to the binding domain without the toxicity to other cells. The immunotoxin is useful in treating graft versus host disease as well as selectively killing tumor cells, such as medulloblastoma and glioblastoma cells.
    Type: Grant
    Filed: January 25, 1989
    Date of Patent: May 4, 1993
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Cetus Corporation
    Inventors: Virginia G. Johnson, Larry Greenfield, Richard J. Youle, Walter Laird
  • Patent number: 5208151
    Abstract: Highly purified derivatives of maltooligosaccharides can be produced at a high yield by reacting, in a mixture of a hydrophilic organic solvent and water, a mixture of maltooligosaccharides or a substance capable of being converted into the maltooligosaccharides upon reaction with an amylase, and an o-glucosyl derivative, with the amylase.The resulting derivatives of maltooligosaccharides are useful as a substrate for the determination of .alpha.-amylase activity in a humor, physiologically active substances, natural dieteic sweetenings, coloring agents and the like.
    Type: Grant
    Filed: October 31, 1990
    Date of Patent: May 4, 1993
    Assignees: Nihon Shokuhin Kako Co., Ltd., Yaizu Suisan Kagaku Kogyo Co., Ltd.
    Inventors: Taichi Usui, Teruo Nakakuki, Kazuo Sakai
  • Patent number: 5206156
    Abstract: The invention relates to a process for the preparation of a particulate antimicrobial product from the LP system of the lactoperoxidase enzyme/oxygen donor/oxidizable substrate (if needed). The process comprises bonding the lactoperoxidase enzyme to a particulate carrier comprising a polysaccharide nucleus, a first lipidic layer and a second phospholipidic layer in such a manner that the enzyme molecules are inserted into this second layer and/or into the first layer. The product according to the invention is obtained by then conditioning in a non-aqueous medium the aforesaid particulate vector and the molecules of the LP system not integrated into said vector. The process of the invention permits adjusting the diffusability of the product and its mobility as a function of the intended applications, without destruction of the LP system.
    Type: Grant
    Filed: May 11, 1990
    Date of Patent: April 27, 1993
    Assignee: Bio Serae Laboratoires SA
    Inventors: Daniel Samain, Frederique Nguyen, Michel Degre
  • Patent number: 5206222
    Abstract: This invention relates to a method to treat a heart attack victim to reduce heart muscle damage. In particular, the invention relates to a metGrant StatementThis research was supported in part by the National Institute of Health, Grant R01 HL40892-01.
    Type: Grant
    Filed: May 22, 1991
    Date of Patent: April 27, 1993
    Assignee: Vanderbilt University
    Inventors: Mervyn B. Forman, Edwin K. Jackson
  • Patent number: 5206356
    Abstract: Synthetic glycosaminosyl transferase-V acceptors and inhibitors are disclosed. Minimal trisaccharide inhibitors and acceptors specific for GnT-V, which is associated with the ability of cells to metastasize are useful, in diagnosis and treatment of conditions characterized by metastatic cells.
    Type: Grant
    Filed: July 15, 1991
    Date of Patent: April 27, 1993
    Assignee: Chembiomed, Ltd.
    Inventors: James M. Pierce, Ole Hindsgaul
  • Patent number: 5206150
    Abstract: A formulation for use in detecting and/or determining peroxidase activity comprises a mixture in solution of tetramethylbenzidine, hydrogen peroxide, a buffering agent and bacitracin as a stabilizing agent. The formulation is used as a peroxidase substrate that is stable in solution for an extended period of time and provides enhanced color sensitivity.
    Type: Grant
    Filed: October 26, 1990
    Date of Patent: April 27, 1993
    Assignee: University of Kentucky Research Foundation
    Inventor: Hsin-Hsiung Tai
  • Patent number: 5206350
    Abstract: This invention relates to a new synthetic process for the preparation of anti-tumor agent Etoposide (VP16-213). the process, which has shorten reaction route, simple procedure, high yield and low materials cost, therefore facilitates the commercial manufacture of etoposide.
    Type: Grant
    Filed: June 7, 1991
    Date of Patent: April 27, 1993
    Assignee: Shanghai Institute of Pharmaceutical Industry
    Inventors: Zhi-guang Wang, Wei-yong Ma, Chun-nian Zhang
  • Patent number: 5206351
    Abstract: A process for the preparation of 2-amino-9-(2,3,5-tri-O-benzyl-beta-D-arabinofuranosyl) adenine (V) is described. The process uses a protected 2,6-di(tri-alkylsilylamino)-9-trialkylsilylpurine (II) which is reacted with protected chlorosugar 2,3,5-tri-O-benzyl-1-chloro-D-arabinofuranose (III) and then the protection groups are removed from the 2 and 6 positions. The process provides a 9-beta-D-arabinofuranosyl-2-fluoroadenine (VII) which is an antileukenine drug.
    Type: Grant
    Filed: June 15, 1990
    Date of Patent: April 27, 1993
    Assignee: Ash Stevens, Inc.
    Inventors: Anica Markovac, Maurice P. LaMontagne
  • Patent number: 5204321
    Abstract: Circulating heparin in a mammal may be neutralized without substantial depletion of platelets or leukocytes by administering to the mammal a heparin neutralizing amount of purified PF4 or rPF4 or a heparin neutralizing fragment thereof.
    Type: Grant
    Filed: June 23, 1992
    Date of Patent: April 20, 1993
    Assignee: Repligen Corporation
    Inventors: Jacquelynn J. Cook, Stefan Niewarowski, Theodore E. Maione
  • Patent number: 5204330
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is a group --CH.sub.2 --X where X is hydrogen, halogen, --CN, --N.sub.3, --OC(O)R.sub.5, --S(O).sub.n R.sub.5, --SH, --OC(O)NHR.sub.5, --NHCONHR.sub.5 or --NR.sub.6 R.sub.7, where R.sub.5 is hydrogen optionally substituted C.sub.1-8 alkyl, or aryl, heteroaryl, aryl C.sub.1-4 alkyl or heteroaryl C.sub.1-4 alkyl in each of which the aromatic moiety is optionally substituted with the proviso that when X is --S(O).sub.n R.sub.5, R.sub.5 does not represent hydrogen, R.sub.6 and R.sub.7 are independently hydrogen or C.sub.116 alkyl, or one of R.sub.6 and R.sub.7 is hydrogen and the other is --formyl, C.sub.2-8 alkanoyl, dialkoxyphosphoryl, aroyl, heteroaroyl, aryl C.sub.1-4 alkanoyl, heteroaryl C.sub.1-4 alkanoyl, C.sub.1-8 alkylsulphonyl, arylsulphonyl, heteroarylsulphonyl, aryl C.sub.1-4 alkylsulphonyl or heteroaryl C.sub.1-4 alkylsulphonyl, where any aromatic moiety in R.sub.6 or R.sub.
    Type: Grant
    Filed: December 6, 1990
    Date of Patent: April 20, 1993
    Assignee: Beecham Group p.l.c.
    Inventors: Michael J. Driver, Alexander R. Greenlees, David T. MacPherson
  • Patent number: 5204247
    Abstract: A new strain Lactobacillus sp. KPB-176, which does not possess strict selectivity for specific media and which involves no reduction in the productivity of polysaccharides even during subculture, was isolated from kefir grains. When this new strain is cultured on a medium containing milk whey and casamino acid or when on a medium containing carbohydrate and yeast extract, capsular polysaccharides are produced in high yields.
    Type: Grant
    Filed: October 30, 1991
    Date of Patent: April 20, 1993
    Assignee: Sumitomo Heavy Industries, Ltd.
    Inventors: Susumu Adachi, Takahiro Toba, Takao Mukai, Takashi Watanabe, Haruhiko Yokoi
  • Patent number: 5204323
    Abstract: The invention provides an antidote to blood anticoagulants comprising Factor VIII or fragments of Factor VIII which retain its activity or a substance which increases its concentration in blood.
    Type: Grant
    Filed: September 20, 1991
    Date of Patent: April 20, 1993
    Assignee: Ciba-Geigy Corporation
    Inventors: Valerie S. Findlay, Roger Kerry, Graham F. Pay, Robert B. Wallis, Keith D. Butler
  • Patent number: 5204456
    Abstract: The invention relates to derivatives of nucleosides and their use for the synthesis of oligonucleotides. These derivatives are in accordance with the formula: ##STR1## in which B represents a radical derived from guanine, cytosine or adenine, whose exocylic NH group is protected by the group ##STR2## with R.sup.1 representing a hydrogen atom or a alkyl radical and R.sup.2 a hydrogen atom, and alkyl radical, an alkoxy radical and optionally substituted aryloxy radical, R.sup.3 represents a hydrogen atom, the dimethoxytrityl radical or the radical ##STR3## R.sup.4 represents a hydrogen atom, the radical of formula: ##STR4## or a radical suitable for the synthesis of polynucelotides and R.sup.5 represents a hydrogen atom or the protected or unprotected hydroxyl OH radical.
    Type: Grant
    Filed: September 20, 1990
    Date of Patent: April 20, 1993
    Assignee: Commissariat a l'Energie Atomique
    Inventors: Didier Molko, Jean-Claude Schulhof, Robert Teoule
  • Patent number: 5204096
    Abstract: A hepatitis B vaccine containing a peptide with an amino acid chain of at least six consecutive amino acids within the pre-S gene coded region of the envelope of hepatitis B virus. The vaccine being free of an amino acid sequence corresponding to the naturally occurring envelope proteins of hepatitis B virus and a physiologically acceptable diluent. The peptide being free or linked to a carrier. The carrier being a conventional carrier or a novel carrier including a lipid vesicle stabilized by cross-linking and having covalently bonded active sites on the outer surface thereon. Such novel carrier being useful not only to link the novel peptide containing an amino acid chain with amino acids within the pre-S gene coded region of the surface antigen or hepatitis B virus, but can also be used to bind synthetic peptide analogues of other viral proteins, as well as bacterial, allergen and parasitic proteins of man and animals.
    Type: Grant
    Filed: April 14, 1989
    Date of Patent: April 20, 1993
    Assignees: New York Blood Center, Inc., California Institute of Technology
    Inventors: Alexander R. Neurath, Stephen B. H. Kent
  • Patent number: 5202433
    Abstract: A polysaccharide derivative prepared by replacing a part or the whole of hydrogen atoms of hydroxyl and/or amino groups of a polysaccharide with one or more atomic groups represented by the following formula (1), (2) or (3) is new and useful for the separation of optical isomers: ##STR1## wherein the number of carbon atoms constituting R is 1 to 30 and R is a group having at least one asymmetric center.
    Type: Grant
    Filed: January 18, 1991
    Date of Patent: April 13, 1993
    Assignee: Daicel Chemical Industries, Ltd.
    Inventors: Yoshio Okamoto, Koichi Hatada
  • Patent number: 5200322
    Abstract: An enzymic method for assaying protein C by the use of a synthetic peptide substrate, wherein the action of interfering substances against said peptide substrate are specifically inhibited, and a measuring kit for the same.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: April 6, 1993
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventor: Kenji Matsumoto
  • Patent number: 5200338
    Abstract: A newly discovered lignin peroxidase enzyme is provided. The enzyme is obtained from a bacterial source and is capable of degrading the lignin portion of lignocellulose in the presence of hydrogen peroxide. The enzyme is extracellular, oxidative, inducible by lignin, larch wood xylan, or related substrates and capable of attacking certain lignin substructure chemical bonds that are not degradable by fungal lignin peroxidases.
    Type: Grant
    Filed: November 30, 1988
    Date of Patent: April 6, 1993
    Assignee: Idaho Research Foundation, Incorporation
    Inventors: Donald L. Crawford, Muralidhara Ramachandra
  • Patent number: 5200515
    Abstract: Compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are each C.sub.16-18 long-chain aliphatic acyl and are the same or different; and pharmacologically acceptable salts thereof are disclosed. These novel compounds are effective against 5-FU-resistant tumor cells, have low toxicity, and are not inactivated by nucleoside phosphorylase in vivo.
    Type: Grant
    Filed: May 16, 1991
    Date of Patent: April 6, 1993
    Assignee: Asahi Kasei Kogyo Kabushiki Kaisha
    Inventors: Satoshi Shuto, Hiromichi Itoh, Takumi Obara, Tatsuro Fujiwara
  • Patent number: 5200324
    Abstract: A method is provided for the screening of senile dementia of the Alzheimer type (Alzheimer's disease) by testing for an anomalous molecular form of acetylcholinesterase in cerebrospinal fluid of a patient.
    Type: Grant
    Filed: August 1, 1991
    Date of Patent: April 6, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Dasakumar S. Navaratnam, John D. Priddle, Brendon I. McDonald, A. David Smith, Kim A. Jobst